Theravance Biopharma Inc (TBPH) : Scion Asset Management scooped up 50,000 additional shares in Theravance Biopharma Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 325,000 shares of Theravance Biopharma Inc which is valued at $8,762,000.Theravance Biopharma Inc makes up approximately 17.05% of Scion Asset Management’s portfolio.
Other Hedge Funds, Including , D. E. Shaw reduced its stake in TBPH by selling 122,057 shares or 29.76% in the most recent quarter. The Hedge Fund company now holds 288,070 shares of TBPH which is valued at $7,766,367. Theravance Biopharma Inc makes up approx 0.02% of D. E. Shaw’s portfolio.Proshare Advisors boosted its stake in TBPH in the latest quarter, The investment management firm added 8,280 additional shares and now holds a total of 39,782 shares of Theravance Biopharma Inc which is valued at $1,072,523. Theravance Biopharma Inc makes up approx 0.01% of Proshare Advisors’s portfolio.Blackrock Investment Management boosted its stake in TBPH in the latest quarter, The investment management firm added 21,149 additional shares and now holds a total of 135,449 shares of Theravance Biopharma Inc which is valued at $3,651,705. Trexquant Investment Lp added TBPH to its portfolio by purchasing 12,056 company shares during the most recent quarter which is valued at $325,030. Theravance Biopharma Inc makes up approx 0.04% of Trexquant Investment Lp’s portfolio.State Board Of Administration Of Florida Retirement System boosted its stake in TBPH in the latest quarter, The investment management firm added 815 additional shares and now holds a total of 25,478 shares of Theravance Biopharma Inc which is valued at $646,632.
Theravance Biopharma Inc opened for trading at $28.26 and hit $29.15 on the upside on Thursday, eventually ending the session at $28.86, with a gain of 1.76% or 0.5 points. The heightened volatility saw the trading volume jump to 2,21,527 shares. Company has a market cap of $1,381 M.
Many Wall Street Analysts have commented on Theravance Biopharma Inc. Theravance Biopharma Inc was Downgraded by BofA/Merrill to ” Underperform” on Aug 3, 2016. Guggenheim Initiated Theravance Biopharma Inc on Jun 20, 2016 to “Buy”, Price Target of the shares are set at $30.Company shares were Reiterated by Leerink Partners on Jun 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 29 from a previous price target of $26 .
Theravance Biopharma Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is engaged to create value from a diverse set of assets: an approved product; a development pipeline of mid- and late-stage assets and a productive research platform designed for long-term growth. VIBATIV (telavancin) its commercial product is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily oral treatment for opioid-induced constipation (OIC). Its earlier-stage clinical assets represent approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease.